menu

226 results

The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients.

van Capelle CI, van der Beek NA, de Vries JM, van Doorn PA, Duivenvoorden HJ, Leshner RT, Hagemans ML, van der Ploeg AT

Journal of inherited metabolic disease, 2012 Mar

doi: 10.1007/s10545-011-9388-3

Gingival overgrowth in Pompe disease: a case report.

de Gijt JP, van Capelle CI, Oosterhuis JW, van der Ploeg AT, van der Wal KG

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2011 Aug

doi: 10.1016/j.joms.2011.03.070

Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.

van der Beek NA, van Capelle CI, van der Velden-van Etten KI, Hop WC, van den Berg B, Reuser AJ, van Doorn PA, van der Ploeg AT, Stam H

Molecular genetics and metabolism

doi: 10.1016/j.ymgme.2011.06.012

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.

Güngör D, de Vries JM, Hop WC, Reuser AJ, van Doorn PA, van der Ploeg AT, Hagemans ML

Orphanet journal of rare diseases, 2011 Jun 01

doi: 10.1186/1750-1172-6-34

Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy.

Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK,

Genetics in medicine : official journal of the American College of Medical Genetics, 2011 Jul

doi: 10.1097/GIM.0b013e3182142966

Burden of illness of Pompe disease in patients only receiving supportive care.

Kanters TA, Hagemans ML, van der Beek NA, Rutten FF, van der Ploeg AT, Hakkaart L

Journal of inherited metabolic disease, 2011 Oct

doi: 10.1007/s10545-011-9320-x

Ptosis, extraocular motility disorder, and myopia as features of pompe disease.

Slingerland NW, Polling JR, van Gelder CM, van der Ploeg AT, Bleyen I

Orbit (Amsterdam, Netherlands), 2011 Mar

doi: 10.3109/01676830.2010.546932

A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers.

van den Berg LE, de Vries JM, Verdijk RM, van der Ploeg AT, Reuser AJ, van Doorn PA

Neuromuscular disorders : NMD, 2011 Mar

doi: 10.1016/j.nmd.2010.11.016

Where do we stand in enzyme replacement therapy in Pompe's disease?

van der Ploeg AT

Neuromuscular disorders : NMD, 2010 Dec

doi: 10.1016/j.nmd.2010.09.011

High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.

de Vries JM, van der Beek NA, Kroos MA, Ozkan L, van Doorn PA, Richards SM, Sung CC, Brugma JD, Zandbergen AA, van der Ploeg AT, Reuser AJ

Molecular genetics and metabolism, 2010 Dec

doi: 10.1016/j.ymgme.2010.08.009

Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.

van Capelle CI, van der Beek NA, Hagemans ML, Arts WF, Hop WC, Lee P, Jaeken J, Frohn-Mulder IM, Merkus PJ, Corzo D, Puga AC, Reuser AJ, van der Ploeg AT

Neuromuscular disorders : NMD, 2010 Dec

doi: 10.1016/j.nmd.2010.07.277

Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density.

van den Berg LE, Zandbergen AA, van Capelle CI, de Vries JM, Hop WC, van den Hout JM, Reuser AJ, Zillikens MC, van der Ploeg AT

Bone, 2010 Sep

doi: 10.1016/j.bone.2010.06.021